Monday, December 23, 2024

Zymtronix and Ginkgo Bioworks Announce Partnership to Produce Enzymes for the Industrialization of Cell-Free Biomanufacturing

Zymtronix, a developer of cell-free process technologies, and Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced a partnership to optimize enzymes used in Zymtronix’s proprietary cell-free platform for the production of important ingredients in food, agriculture, cosmetics and pharmaceuticals.

Enzymatic biocatalysis is a powerful manufacturing technology that can enable the production of a wide range of chemicals and molecules. Zymtronix’s cell-free platform is designed to solve challenges associated with traditional biocatalysis and seeks to enable the production of a wide range of products with precision and productivity.

Also Read: Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration

Ginkgo Enzyme Services offers partners end-to-end support for the discovery, optimization, and production of enzymes for diverse applications. Through the partnership, Ginkgo will leverage its suite of enzyme services to engineer enzymes for Zymtronix’s applications using metagenomic enzyme discovery as well as improve enzyme expression and production host performance.

“We’re thrilled to welcome Zymtronix to the platform and support their applications in sustainable ingredients and beyond,” said Ena Cratsenburg, Chief Business Officer at Ginkgo Bioworks. “We built out Ginkgo’s platform to serve a wide variety of enzyme discovery, engineering, optimization and scale up efforts, and we’re so excited for the work to come in this partnership. Zymtronix’s cell-free biomanufacturing platform is pioneering solutions for various industries, and we’re eager to leverage our end-to-end capabilities and help expand its efforts in transforming the way enzymes are used.”

“This partnership will greatly accelerate our work of bringing the precision and scalability of cell-free biomanufacturing and sustainable ingredients to market starting with alternatives to animal sources; Ginkgo is uniquely able to support us with both enzyme engineering and strain expression, helping us continue to accelerate commercialization,” said Stéphane Corgié, CEO-CTO and founder, Zymtronix. “We hope to extend this partnership in the future to facilitate the production of multiple end-market products.”

SOURCE: PR Newswire

Subscribe Now

    Hot Topics